These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32147979)

  • 1. A Cross-sectional Survey on the Preference of Patients with Rheumatoid Arthritis for Route of Administration of Disease-Modifying Anti-Rheumatic Drugs: Oral Target-Specific Versus Parenteral Biologic.
    Edel Y; Sagy I; Pokroy-Shapira E; Oren S; Dortort Lazar A; Egbaria M; Shiber S; Tal BS; Molad Y
    Isr Med Assoc J; 2020 Mar; 22(3):154-159. PubMed ID: 32147979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
    Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases.
    Fazaa A; Makhlouf Y; Ben Ouhiba A; Miladi S; Sellami M; Ouenniche K; Souabni L; Kassab S; Chekili S; Zakraoui L; Ben Abdelghani K; Laatar A
    Therapie; 2021; 76(5):467-474. PubMed ID: 32948325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.
    Aaltonen KJ; Turunen JH; Sokka T; Puolakka K; Valleala H
    Clin Exp Rheumatol; 2016; 34(4):694-7. PubMed ID: 27213997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
    Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
    Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
    Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rheumatoid arthritis in Turkey: a questionnaire study.
    Direskeneli H; Akkoç N; Bes C; Cakir N; Cefle A; Cobankara V; Dalkilic E; Dinc A; Ertenli I; Gul A; Hamuryudan V; Inanc M; Kalyoncu U; Karaaslan Y; Kasifoglu T; Keser G; Keskin G; Kisacik B; Kiraz S; Masatlioglu S; Onat AM; Ozbek S; Ozturk MA; Pamuk ON; Pay S; Pirildar T; Sayarlioglu M; Senel S; Senturk T; Tasan D; Terzioglu E; Yazici A; Yucel E
    Clin Exp Rheumatol; 2014; 32(4):477-83. PubMed ID: 24960289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
    Doria A; Zavaglia D
    Clin Exp Rheumatol; 2019; 37(5):862-871. PubMed ID: 31376250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study.
    Heidari P; Cross W; Weller C; Nazarinia M; Crawford K
    Int J Rheum Dis; 2019 Apr; 22(4):555-566. PubMed ID: 30924291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
    Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry.
    Black RJ; Lester S; Buchbinder R; Barrett C; Lassere M; March L; Whittle S; Hill CL
    Arthritis Res Ther; 2017 Nov; 19(1):253. PubMed ID: 29141677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.
    Ichinose K; Shimizu T; Umeda M; Fukui S; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Tamai M; Nakamura H; Sato S; Origuchi T; Kawakami A
    J Immunol Res; 2018; 2018():6259010. PubMed ID: 30186881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
    Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
    Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.